Vident Advisory LLC Acquires 122,989 Shares of Exelixis, Inc. $EXEL

Key Points

• Vident Advisory LLC significantly increased its holdings in Exelixis, Inc. by 78.9% during the first quarter, owning approximately 0.10% of the company valued at $10.3 million.
• Several institutional investors, including Hemington Wealth Management and Harbour Investments, also expanded their positions in Exelixis, indicating strong market interest with institutions owning over 85% of the company’s stock.
• Exelixis reported earnings of $0.75 per share for the last quarter, exceeding analysts' expectations, though revenue decreased by 10.8% year-over-year.

Vident Advisory LLC lifted its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 78.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 278,863 shares of the biotechnology company's stock after buying an additional 122,989 shares during the quarter. Vident Advisory LLC owned about 0.10% of Exelixis worth $10,296,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Hemington Wealth Management grew its stake in shares of Exelixis by 211.3% in the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock valued at $28,000 after buying an additional 522 shares in the last quarter. Colonial Trust Co SC boosted its position in Exelixis by 616.9% during the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 765 shares during the period. Bartlett & CO. Wealth Management LLC bought a new stake in Exelixis during the first quarter worth approximately $37,000. Costello Asset Management INC bought a new stake in Exelixis during the first quarter worth approximately $39,000. Finally, Harbour Investments Inc. boosted its position in Exelixis by 900.0% during the first quarter. Harbour Investments Inc. now owns 1,100 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 990 shares during the period. Institutional investors own 85.27% of the company's stock.

Exelixis Stock Up 0.3%

Exelixis stock traded up $0.10 during mid-day trading on Thursday, hitting $37.06. 510,187 shares of the company were exchanged, compared to its average volume of 3,011,051. The business has a fifty day moving average of $40.84 and a 200 day moving average of $39.51. Exelixis, Inc. has a 1-year low of $25.12 and a 1-year high of $49.62. The company has a market capitalization of $9.98 billion, a PE ratio of 17.83, a price-to-earnings-growth ratio of 0.77 and a beta of 0.32.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm had revenue of $568.26 million during the quarter, compared to analyst estimates of $574.36 million. During the same period in the prior year, the company posted $0.84 earnings per share. The business's revenue for the quarter was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. Research analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

EXEL has been the subject of a number of recent analyst reports. Barclays upped their target price on Exelixis from $29.00 to $40.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 10th. Zacks Research cut Exelixis from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 26th. JMP Securities reaffirmed a "market outperform" rating and set a $50.00 target price on shares of Exelixis in a research report on Tuesday, July 29th. Truist Financial decreased their target price on Exelixis from $56.00 to $49.00 and set a "buy" rating for the company in a research report on Tuesday, July 29th. Finally, Bank of America upped their target price on Exelixis from $45.00 to $46.00 and gave the stock a "neutral" rating in a research report on Thursday, June 5th. Thirteen equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $44.06.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.